Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

NCT01428492 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01428492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01428492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Oral AKT Inhibitor GSK2110183 Administered in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Novartis
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2011
Completion date
October 31, 2015
Enrollment
90 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma